November 20th, 2026FDA approves once-weekly somapacitan for children with Turner syndromeThe FDA approved once-weekly somapacitan-beco for growth failure in Turner syndrome in children aged 2.5+ years, based on phase 3 REAL8 data.Read more
November 16th, 2026Etavopivat for sickle cell disease submitted to FDA and EMANovo Nordisk filed etavopivat for SCD in patients aged 12+, backed by phase 3 HIBISCUS data showing a 27% drop in vaso-occlusive crises vs placebo.Read more
November 4th, 2026November 2026 preview: 4 FDA decisions to watch in pediatric careFind out the 4 FDA decisions to watch in November 2026 for pediatric care.Read more
October 26th, 2026Zilurgisertib reduces HO volume in children aged 6 to 11 with FOPIn PROGRESS Cohort 2, zilurgisertib reduced total HO volume vs placebo at 24 weeks in children aged 6 to 11 with FOP, with no new HO lesions.Read more
October 21st, 2026FDA approves berotralstat oral pellets for HAE in patients 12 and upFDA approves berotralstat 150-mg oral pellets for HAE prophylaxis in patients 12+ who cannot or prefer not to swallow capsules.Read more
November 20th, 2026Contemporary Pediatrics week in review: November 16-20, 2026Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.Read more
November 20th, 2026Puberty brings new cardiovascular risks for girlsExperts explain how puberty affects lipid levels, body composition, and mental health, with implications for cardiovascular screening in adolescent girls.Read more
November 20th, 2026New AHA advisory calls for lifelong cardiovascular care in womenExperts discuss a new AHA advisory linking cardiovascular risk across a woman's life, from puberty through pregnancy, menopause, and beyond.Read more